TY - JOUR
T1 - Lifetime estrogen exposure and domain-specific cognitive performance
T2 - results from the IGNITE study
AU - Watts, Amber
AU - Donofry, Shannon
AU - Ripperger, Hayley
AU - Eklund, Nicole M.
AU - Wan, Lu
AU - Kang, Chaeryon
AU - Grove, George
AU - Oberlin, Lauren E.
AU - Gujral, Swathi
AU - Vidoni, Eric D.
AU - Burns, Jeffrey M.
AU - McAuley, Edward
AU - Hillman, Charles H
AU - Kramer, Arthur F
AU - Kamboh, M. Ilyas
AU - Erickson, Kirk I.
N1 - JB received research support from the NIH, research support to conduct clinical trials (paid to institution) from Eli Lilly, Amylyx, Biogen, Eisai, AbbVie, Astra-Zeneca, Roche, and Ionis. Consultant for Renew Research, Eisai, Eli Lilly, Labcorp, Roche, Renew Biotechnologies, Abbvie, Novo Nordisk. JB was also part of the Data Monitoring Committee for Intra-Cellular Therapies, Inc. KE was part of the scientific advisory board for NeoAuvra, Inc., and MedRhythms, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. The reviewer CA declared a shared affiliation with the author(s) LO to the handling editor at the time of review.
The author(s) declare that financial support was received for the research and/or publication of this article. The IGNITE study was funded by the National Institute on Aging, R01 AG053952, R35 AG072307. Use of REDCap for the project was sponsored by the Clinical and Translational Science Institute at the University of Pittsburgh Grant Number UL1-TR-001857. AW was supported by an NIH grant from NIGMS and OD 1P20GM152280.
PY - 2025
Y1 - 2025
N2 - Introduction: Disruptions in estrogen exposure (i.e., surgically induced menopause) have been linked to poorer cognitive aging and dementia risk. Hormone therapy use (e.g., birth control, menopausal hormone therapy) has shown mixed associations with cognitive performance, possibly due to limited cognitive test batteries. To address previous inconsistencies, we investigated baseline data from Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE). We hypothesized that (1) oophorectomy prior to natural menopause would be associated with poorer cognitive performance, (2) timing and duration of birth control and menopausal hormone therapy would influence associations with cognitive performance, and (3) APOE4 carrier status would interact with oophorectomy and hormone therapy to influence cognitive performance. Methods: In 461 post-menopausal females (M age = 69.6) we assessed oophorectomy and hormone therapy use to examine associations with the Montreal Cognitive Assessment (MoCA) and factor-analytically derived composite scores for episodic memory, processing speed, working memory, executive function/attentional control, and visuospatial processing. Results: Hypothesis (1) We did not observe associations between oophorectomy prior to natural menopause and poorer cognitive performance. However, hormone therapy use, started on average within 2 years of oophorectomy, was associated with better episodic memory (β = 0.106, p = 0.02), working memory (β = 0.120, p = 0.005), and visuospatial processing (β = 0.095, p = 0.03). Hypothesis (2) Birth control use was associated with better performance on the MoCA (β = 0.093, p = 0.04), working memory (β = 0.102, p = 0.02), and executive function/attentional control (β = 0.103, p = 0.02). However, duration and timing of birth control and menopausal hormone therapy were not associated with cognitive performance. Hypothesis (3) We did not observe significant interactions between APOE4 status and oophorectomy or hormone therapy in their associations with cognitive performance. Discussion: Our results suggest exposure to estrogen during adulthood, specifically birth control and hormone therapy among women undergoing pre-menopausal oophorectomy, benefits cognitive function in older adulthood. Our comprehensive cognitive battery allowed us to examine cognitive function with a high degree of granularity. Future work should evaluate causal mechanisms of associations between lifetime estrogen exposure and later life cognitive function.
AB - Introduction: Disruptions in estrogen exposure (i.e., surgically induced menopause) have been linked to poorer cognitive aging and dementia risk. Hormone therapy use (e.g., birth control, menopausal hormone therapy) has shown mixed associations with cognitive performance, possibly due to limited cognitive test batteries. To address previous inconsistencies, we investigated baseline data from Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE). We hypothesized that (1) oophorectomy prior to natural menopause would be associated with poorer cognitive performance, (2) timing and duration of birth control and menopausal hormone therapy would influence associations with cognitive performance, and (3) APOE4 carrier status would interact with oophorectomy and hormone therapy to influence cognitive performance. Methods: In 461 post-menopausal females (M age = 69.6) we assessed oophorectomy and hormone therapy use to examine associations with the Montreal Cognitive Assessment (MoCA) and factor-analytically derived composite scores for episodic memory, processing speed, working memory, executive function/attentional control, and visuospatial processing. Results: Hypothesis (1) We did not observe associations between oophorectomy prior to natural menopause and poorer cognitive performance. However, hormone therapy use, started on average within 2 years of oophorectomy, was associated with better episodic memory (β = 0.106, p = 0.02), working memory (β = 0.120, p = 0.005), and visuospatial processing (β = 0.095, p = 0.03). Hypothesis (2) Birth control use was associated with better performance on the MoCA (β = 0.093, p = 0.04), working memory (β = 0.102, p = 0.02), and executive function/attentional control (β = 0.103, p = 0.02). However, duration and timing of birth control and menopausal hormone therapy were not associated with cognitive performance. Hypothesis (3) We did not observe significant interactions between APOE4 status and oophorectomy or hormone therapy in their associations with cognitive performance. Discussion: Our results suggest exposure to estrogen during adulthood, specifically birth control and hormone therapy among women undergoing pre-menopausal oophorectomy, benefits cognitive function in older adulthood. Our comprehensive cognitive battery allowed us to examine cognitive function with a high degree of granularity. Future work should evaluate causal mechanisms of associations between lifetime estrogen exposure and later life cognitive function.
KW - aging
KW - cognition
KW - estrogen
KW - menopause
KW - oophorectomy
KW - women
UR - http://www.scopus.com/inward/record.url?scp=105002659338&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105002659338&partnerID=8YFLogxK
U2 - 10.3389/fnagi.2025.1524474
DO - 10.3389/fnagi.2025.1524474
M3 - Article
C2 - 40248334
AN - SCOPUS:105002659338
SN - 1663-4365
VL - 17
JO - Frontiers in Aging Neuroscience
JF - Frontiers in Aging Neuroscience
M1 - 1524474
ER -